Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 6/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.31 |
| ▸ | CXCR3 | P49682 | 5/20 | 0.31 |
| ▸ | BRD4 | O60885 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27125769 | 0.81 | HSD17B13 (0.35) | PDE1BTNIK | |
| SCHEMBL27126075 | 0.80 | HSP90AA1 (0.32) | BRD4KDM4EALDH1A1HTT | |
| SCHEMBL27129979 | 0.75 | PDE1B (0.34) | PDE1BNPSR1 | |
| SCHEMBL30781119 | 0.73 | SOS1 (0.37) | — | |
| SCHEMBL27128979 | 0.72 | KMT2A (0.32) | MAP4K4 | |
| Hydrochloric Acid SCHEMBL30781456 | 0.72 | SOS1 (0.38) | — | |
| SCHEMBL30781283 | 0.71 | USP7 (0.44) | PDE1B | |
| SCHEMBL30781268 | 0.71 | USP7 (0.44) | PDE1B | |
| SCHEMBL30781258 | 0.71 | KCNH2 (0.38) | PDE1B | |
| SCHEMBL30781299 | 0.71 | USP7 (0.44) | PDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150362-A1 | Substituted Pyrrolotriazines | MOLECURE S.A. (PL) | 2024-05-09 | — | — | US | disclosed |
| WO-2024042494-A1 | SUBSTITUTED PYRROLOTRIAZINES | MOLECURE SA (PL) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024042494-A1 | SUBSTITUTED PYRROLOTRIAZINES | MOLECURE SA (PL) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150362-A1 | Substituted Pyrrolotriazines | USP7, UBA7, USP5 | PDE1B 2058/4885HPGD 2822/4885TNIK 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.